Greg Lazar, Ph.D.

Director and Senior Scientist, Antibody Engineering at Genentech

Greg Lazar received his BS in Molecular & Cell Biology and Chemistry from Penn State, his PhD in Molecular & Cell Biology from the University of California at Berkeley, and did postdoctoral research at the University of Cambridge, UK. Previously he led research groups at Eli Lilly and Xencor. Currently he is Director and Senior Scientist in Antibody Engineering at Genentech where he oversees antibody technology platforms, high-throughput protein production, and infrastructure for automation and informatics. His research group is focused on the development of novel antibody technologies to enable next generation therapeutics to treat unmet medical needs in oncology and neuroscience.